Improved linker technologies and broadening payload options mark a coming of age for these precision cancer therapies.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Author information
Authors and Affiliations
London, UK
Melanie Senior
About this article
Cite this article
Senior, M. Cancer-targeting antibody–drug conjugates drive dealmaking frenzy.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02168-5
Download citation
Published: 26 February 2024
DOI: https://doi.org/10.1038/s41587-024-02168-5
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-024-02168-5
